Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,378 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma.
Iiyama T, Udaka K, Takeda S, Takeuchi T, Adachi YC, Ohtsuki Y, Tsuboi A, Nakatsuka S, Elisseeva OA, Oji Y, Kawakami M, Nakajima H, Nishida S, Shirakata T, Oka Y, Shuin T, Sugiyama H. Iiyama T, et al. Among authors: nakajima h. Microbiol Immunol. 2007;51(5):519-30. doi: 10.1111/j.1348-0421.2007.tb03940.x. Microbiol Immunol. 2007. PMID: 17579261 Free article. Clinical Trial.
Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues.
Tsuboi A, Oka Y, Udaka K, Murakami M, Masuda T, Nakano A, Nakajima H, Yasukawa M, Hiraki A, Oji Y, Kawakami M, Hosen N, Fujioka T, Wu F, Taniguchi Y, Nishida S, Asada M, Ogawa H, Kawase I, Sugiyama H. Tsuboi A, et al. Among authors: nakajima h. Cancer Immunol Immunother. 2002 Dec;51(11-12):614-20. doi: 10.1007/s00262-002-0328-9. Epub 2002 Oct 18. Cancer Immunol Immunother. 2002. PMID: 12439606 Free PMC article.
The lck promoter-driven expression of the Wilms tumor gene WT1 blocks intrathymic differentiation of T-lineage cells.
Li H, Oka Y, Tsuboi A, Yamagami T, Miyazaki T, Yusa S, Kawasaki K, Kishimoto Y, Asada M, Nakajima H, Kanato K, Nishida S, Masuda T, Murakami M, Hosen N, Kawakami M, Ogawa H, Melchers F, Kawase I, Oji Y, Sugiyama H. Li H, et al. Among authors: nakajima h. Int J Hematol. 2003 Jun;77(5):463-70. doi: 10.1007/BF02986614. Int J Hematol. 2003. PMID: 12841384
Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis.
Oka Y, Tsuboi A, Murakami M, Hirai M, Tominaga N, Nakajima H, Elisseeva OA, Masuda T, Nakano A, Kawakami M, Oji Y, Ikegame K, Hosen N, Udaka K, Yasukawa M, Ogawa H, Kawase I, Sugiyama H. Oka Y, et al. Among authors: nakajima h. Int J Hematol. 2003 Jul;78(1):56-61. doi: 10.1007/BF02983241. Int J Hematol. 2003. PMID: 12894852 Clinical Trial.
WT1 peptide-based immunotherapy for patients with lung cancer: report of two cases.
Tsuboi A, Oka Y, Osaki T, Kumagai T, Tachibana I, Hayashi S, Murakami M, Nakajima H, Elisseeva OA, Fei W, Masuda T, Yasukawa M, Oji Y, Kawakami M, Hosen N, Ikegame K, Yoshihara S, Udaka K, Nakatsuka S, Aozasa K, Kawase I, Sugiyama H. Tsuboi A, et al. Among authors: nakajima h. Microbiol Immunol. 2004;48(3):175-84. doi: 10.1111/j.1348-0421.2004.tb03503.x. Microbiol Immunol. 2004. PMID: 15031530 Free article.
WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone.
Nakajima H, Kawasaki K, Oka Y, Tsuboi A, Kawakami M, Ikegame K, Hoshida Y, Fujiki F, Nakano A, Masuda T, Wu F, Taniguchi Y, Yoshihara S, Elisseeva OA, Oji Y, Ogawa H, Azuma I, Kawase I, Aozasa K, Sugiyama H. Nakajima H, et al. Cancer Immunol Immunother. 2004 Jul;53(7):617-24. doi: 10.1007/s00262-003-0498-0. Epub 2004 Feb 7. Cancer Immunol Immunother. 2004. PMID: 15175906 Free PMC article.
Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.
Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H, Elisseeva OA, Oji Y, Kawakami M, Ikegame K, Hosen N, Yoshihara S, Wu F, Fujiki F, Murakami M, Masuda T, Nishida S, Shirakata T, Nakatsuka S, Sasaki A, Udaka K, Dohy H, Aozasa K, Noguchi S, Kawase I, Sugiyama H. Oka Y, et al. Among authors: nakajima h. Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13885-90. doi: 10.1073/pnas.0405884101. Epub 2004 Sep 13. Proc Natl Acad Sci U S A. 2004. PMID: 15365188 Free PMC article. Clinical Trial.
WT1(235), a ninemer peptide derived from Wilms' tumor gene product, is a candidate peptide for the vaccination of HLA-A*0201-positive patients with hematopoietic malignancies.
Li Z, Oka Y, Tsuboi A, Masuda T, Tatsumi N, Kawakami M, Fujioka T, Sakaguchi N, Nakajima H, Fujiki F, Udaka K, Oji Y, Kawase I, Sugiyama H. Li Z, et al. Among authors: nakajima h. Int J Hematol. 2005 Dec;82(5):458-9. doi: 10.1532/IJH97.05107. Int J Hematol. 2005. PMID: 16533753 No abstract available.
Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
Fujiki F, Oka Y, Tsuboi A, Kawakami M, Kawakatsu M, Nakajima H, Elisseeva OA, Harada Y, Ito K, Li Z, Tatsumi N, Sakaguchi N, Fujioka T, Masuda T, Yasukawa M, Udaka K, Kawase I, Oji Y, Sugiyama H. Fujiki F, et al. Among authors: nakajima h. J Immunother. 2007 Apr;30(3):282-93. doi: 10.1097/01.cji.0000211337.91513.94. J Immunother. 2007. PMID: 17414319
Clinical and immunologic responses to very low-dose vaccination with WT1 peptide (5 microg/body) in a patient with chronic myelomonocytic leukemia.
Kawakami M, Oka Y, Tsuboi A, Harada Y, Elisseeva OA, Furukawa Y, Tsukaguchi M, Shirakata T, Nishida S, Nakajima H, Morita S, Sakamoto J, Kawase I, Oji Y, Sugiyama H. Kawakami M, et al. Among authors: nakajima h. Int J Hematol. 2007 Jun;85(5):426-9. doi: 10.1532/IJH97.06194. Int J Hematol. 2007. PMID: 17562620
4,378 results